January 10, 2017 / 1:32 AM / 9 months ago

Japan's Takeda expects annual sales of Ariad's lung cancer drug to exceed $1 bln

TOKYO, Jan 10 (Reuters) - Japan’s Takeda Pharmaceutical Co Ltd expects annual sales from new lung cancer drug brigatinib, added to its portfolio with the acquisition of Ariad Pharmaceuticals Inc, will exceed $1 billion, the Japanese company’s CEO said on Tuesday.

“It has the potential to be the best in class,” Christophe Weber said during a conference after Takeda announced the $5.2 billion acquisition of Ariad in a bid to boost its oncology pipeline.

Reporting by Tim Kelly; Editing by Michael Perry

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below